Vancomycin-resistant Enterococcus faecium infection; nosocomial pneumonia or community-acquired pneumonia caused by Staphylococcus aureus, or Streptococcus pneumonia; complicated SSTI (skin, soft tissue infection).

Linezolid is a synthetic oxazolidinone antimicrobial agent. Inhibits bacterial protein synthesis by binding to bacterial 23S ribosomal RNA of the 50S subunit. This prevents the formation of a functional 70S initiation complex, which is essential for the bacterial translation process.

Bioavailability is approximately 100%; plasma protein binding 31%; well penetration into a variety of tissues; undergoing hepatic oxidation to two inactive metabolites; excretion: urine (30% as parent drug). Elimination half-life: 4-5 hrs. Linezolid should be given after hemodialysis (removed by hemodialysis).

Hypersensitivity to linezolid or any of the other product components

C

Excretion in breast milk unknown

Diarrhea (3 % to 11.0%), headache (0.5% to 11.3%), nausea (3.4% to 9.6%), myelosuppression (more common in patients receiving linezolid for ＞2 weeks).

Adult and child ≧12 years: IV or Orally 600 mg Q12H;
neonates <7 days of age :10 mg/kg Q12H; neonates >7 days of age : 10 mg/kg Q8H.
Dose adjustments are unnecessary when converting from IV to oral administration .
No dosage adjustment is recommended for renal or hepatic impairment patient.

No dosage adjustment is recommended for renal impairment patient.

No dosage adjustment is recommended for hepatic impairment patient.